Madrigal Pharmaceuticals, Inc. (MDGL) NASDAQ

Currency In USD

Madrigal Pharmaceuticals, Inc.

Address

Four Tower Bridge

West Conshohocken, PA 19428

United States of America (the)

Phone

267 824 2827

Website

https://www.madrigalpharma.com

Sector

Healthcare

Industry

Biotechnology

Employees

528

First IPO Date

February 06, 2007

Key Executives

Name	Title	Pay	Year Born
William J. Sibold	Chief Executive Officer, President & Director	2.37M	1966
Shannon Kelley	Executive Vice President, Chief Legal Officer & Corporate Secretary	1.07M	1975
David Soergel	Executive VP & Chief Medical Officer	1.08M	1968
Carole Huntsman	Executive Vice President & Chief Commercial Officer	1.08M	1965
Mardi C. Dier	Executive Vice President & Chief Financial Officer	1.21M	1964
Rebecca A. Taub	Founder, Senior Scientific & Medical Advisor and Director	1.22M	1952
Clint Wallace	Executive Vice President & Chief Human Resources Officer	0	N/A
Mark Underwood	Executive Vice President of Business Planning & Operations	0	N/A
Ronald Filippo	Executive Vice President & Chief Information Officer	0	N/A
Rita Thakkar	Senior VP & Chief Accounting Officer	0	1974
Tina E. Ventura	Chief Investor Relations Officer	0	N/A

Description

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.